Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 20 2017 - 4:01PM
Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley,
Chairman and Chief Executive Officer, will participate in a
corporate overview and fireside chat at the LEERINK Partners
Roundtable Series: Rare Disease & Immuno-Oncology in New York,
NY on Wednesday, September 27, 2017 at 1:00 p.m. ET.
A live webcast of the presentation can be
accessed through the Investors section of the Amicus Therapeutics
corporate web site at http://ir.amicustherapeutics.com/events.cfm,
and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company
at the forefront of therapies for rare and orphan diseases. The
Company has a robust pipeline of advanced therapies for a broad
range of human genetic diseases. Amicus’ lead programs in
development include the small molecule pharmacological chaperone
migalastat as a monotherapy for Fabry disease, as well as novel
enzyme replacement therapy (ERT) and biologic products for Fabry
disease, Pompe disease, and other rare and devastating
diseases.
CONTACTS:
Investors/Media:Amicus
TherapeuticsSara Pellegrino, IRCSenior Director, Investor
Relationsspellegrino@amicusrx.com (609) 662-5044
Media:W2O GroupJennifer Paganelli
jpaganelli@purecommunications.com (347) 658-8290
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024